Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies
The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
The high prevalence of human serum antibodies against adeno-associated virus type 2 (AAV) vectors represents a potential limitation for in vivo applications. Consequently, the development of AAV vectors able to escape antibody binding and neutralization is of importance. To identify capsid domains which contain major immunogenic epitopes, six AAV capsid mutants carrying peptide insertions in surface exposed loop regions (I-261, I-381, I-447, I-534, I-573, I-587) were analyzed. Two of these mutants, I-534 and I-573, showed an up to 70% reduced affinity for AAV antibodies as compared to wild-type AAV in the majority of serum samples. In addition, AAV mutant I-587 but not wild-type AAV efficiently transduced cells despite the presence of neutralizing antisera. Taken together, the results show that major neutralizing effects of human AAV antisera might be overcome by the use of AAV capsid mutants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although a previous report demonstrated that RGD insertions at amino acid 588 on the AAV2 capsid could disrupt an antibody binding epitope,65”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [65]
Citations
Cites
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Real-Time Single-Molecule Imaging of the Infection Pathway of an Adeno-Associated Virus
Seisenberger, G., Ried, M. U., Endreß, T., Büning, H., Hallek, M., & Bräuchle, C. (2001) · Science · doi:10.1126/science.1064103 · Cited by 820
Self-citationαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532
The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications
Tsao, J., Chapman, M. S., Agbandje, M., Keller, W., Smith, K., Wu, H., Luo, M., Smith, T. J., Rossmann, M. G., Compans, R. W., et al. (1991) · Science · doi:10.1126/science.2006420 · Cited by 512
Flotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., & Carter, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10613 · Cited by 490
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Self-citationWu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)
Erles, K., Seb�kov�, P., & Schlehofer, J. R. (1999) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(199911)59:3<406::aid-jmv22>3.0.co;2-n · Cited by 342
Cloning and Characterization of Adeno-Associated Virus Type 5
Chiorini, J. A., Kim, F., Yang, L., & Kotin, R. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.2.1309-1319.1999 · Cited by 332
Douar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273
Self-citationSanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., & Engelhardt, J. F. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9184-9196.2000 · Cited by 269
Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids
Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., & Weitzman, M. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0345 · Cited by 241
Chang, S. F., Sgro, J. Y., & Parrish, C. R. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6858-6867.1992 · Cited by 229
In vitro selection of viral vectors with modified tropism: the adeno-associated virus display
Perabo, L., Büning, H., Kofler, D. M., Ried, M. U., Girod, A., Wendtner, C. M., Enssle, J., & Hallek, M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00123-0 · Cited by 229
Self-citationEfficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells
Nicklin, S. A., Buening, H., Dishart, K. L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A. J., Ali, R. R., Hallek, M., & Baker, A. H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0424 · Cited by 219
Self-citationStructure, Sequence, and Function Correlations among Parvoviruses
Chapman, M. S., & Rossmann, M. G. (1993) · Virology · doi:10.1006/viro.1993.1288 · Cited by 201
Grimm, D., Kern, A., Pawlita, M., Ferrari, F. K., Samulski, R. J., & Kleinschmidt, J. A. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300946 · Cited by 195
Self-citationDynamin Is Required for Recombinant Adeno-Associated Virus Type 2 Infection
Duan, D., Li, Q., Kao, A. W., Yue, Y., Pessin, J. E., & Engelhardt, J. F. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.10371-10376.1999 · Cited by 186
Strassheim, M. L., Gruenberg, A., Veijalainen, P., Sgro, J.-Y., & Parrish, C. R. (1994) · Virology · doi:10.1006/viro.1994.1020 · Cited by 175
Shi, W., Arnold, G. S., & Bartlett, J. S. (2001) · Human Gene Therapy · doi:10.1089/104303401750476212 · Cited by 167
Electron cryo‐microscopy and image reconstruction of adeno‐associated virus type 2 empty capsids
Kronenberg, S., Kleinschmidt, J. A., & Böttcher, B. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve234 · Cited by 161
Self-citationWistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147
Self-citationInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136
Adeno-associated virus 2 co-receptors?
Qiu, J., Mizukami, H., & Brown, K. E. (1999) · Nature Medicine · doi:10.1038/8328 · Cited by 135
Ried, M. U., Girod, A., Leike, K., Büning, H., & Hallek, M. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4559-4566.2002 · Cited by 132
Self-citationThe Structure of Human Parvovirus B19 at 8 Å; Resolution
Agbandje, M., Kajigaya, S., McKENNA, R. V., Young, N. S., & Rossmann, M. G. (1994) · Virology · doi:10.1006/viro.1994.1460 · Cited by 116
Xiao, W., Chirmule, N., Schnell, M. A., Tazelaar, J., Hughes, J. V., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0045 · Cited by 114
Chipman, P. R., Agbandje-McKenna, M., Kajigaya, S., Brown, K. E., Young, N. S., Baker, T. S., & Rossmann, M. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7502 · Cited by 106
Adeno‐associated virus vectors and hematology
Russell, D. W., & Kay, M. A. (1999) · Blood · doi:10.1182/blood.v94.3.864.415k34_864_874 · Cited by 104
Fisher-Adams, G., Wong, K. J., Podsakoff, G., Forman, S., & Chatterjee, S. (1996) · Blood · doi:10.1182/blood.v88.2.492.bloodjournal882492 · Cited by 103
Integrin αVβ5 Is Not Involved in Adeno-Associated Virus Type 2 (AAV2) Infection
Qiu, J., & Brown, K. E. (1999) · Virology · doi:10.1006/viro.1999.0010 · Cited by 51
Smith, T. J. (2001) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05783-4_1 · Cited by 30
Cited by
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
“However, combining capsid modification and genome modification to produce an optimized AAV serotype vector can reduce affinity with neutralizing antibodies, thereby reducing host immune response and improving delivery efficiency [127].”
BackgroundAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Metadata
- Authors
- Huttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- German Cancer Research Center (DE)
- Helmholtz Munich (DE)
- Venue
- Gene Therapy
- Published
- 2003-11-17
- Volume
- 10
- Issue
- 26
- Pages
- 2139-2147
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2070754430
- Cited by
- 124
- References
- 46
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 12 · 2021: 6 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 2 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus type 2, AAV capsid, capsid mutants, antibody neutralization, human serum antibodies, immunogenic epitopes, antibody affinity, transduction efficiency, adeno-associated virus vectors
- MeSH terms
- Dependovirus, Antibodies, Viral, Antibody Affinity, Capsid, Genetic Vectors, HeLa Cells, Humans, Immune Sera, Mutation, Transduction, Genetic, Mutagenesis, Insertional
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.